HealthQuad Leads INR 117 Cr Investment in Beta Drugs for Minority Stake The Panchkula-based pharmaceutical manufacturer aims to use the fresh funds to accelerate its growth and aspires to be among the top five oncology companies in India over the next five years.

By Entrepreneur Staff

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Freepik

Beta Drugs, a vertically integrated oncology-focused pharmaceutical company, has raised INR 117 crore in primary capital from HealthQuad Fund II (HealthQuad), alongside a Singapore-based investment fund and a private wealth management firm, in exchange for a minority stake.

The funding will drive Beta Drugs' global expansion and bolster its operational capabilities. "Their investment and expertise will play a pivotal role in accelerating our growth journey as we strive to position ourselves among the top five oncology companies in India over the next five years," said Rahul Batra, Chairman and Managing Director of Beta Drugs.

Founded in 2005, Beta Drugs boasts a comprehensive portfolio covering chemotherapy, targeted therapies, hormonal treatments, and supportive care.

The company has established a strong domestic presence and expanded into over 46 international markets, with accreditations from regulatory authorities in regions such as Brazil and the EU. Remarkably, Beta Drugs claims that it was the first Indian company to introduce oncology drugs in suspension form, demonstrating its commitment to innovation.

HealthQuad's Partner Ajay Mahipal highlighted the firm's confidence in Beta Drugs' potential: "With its strong manufacturing and R&D capabilities, Beta Drugs is well-positioned to enhance affordability for middle- and lower-income segments while improving access in tier II and III cities. Their new product launches, expanding export markets, and experienced leadership team position the company for substantial growth and value creation."

HealthQuad, a healthcare transformation fund, has a robust portfolio that spans AI, data analytics, diagnostics, and pharma distribution. Its support is expected to amplify Beta Drugs' market impact and product reach.

O3 Capital acted as the exclusive advisor for the transaction, with DSK Legal, Universal Legal, and Desai and Diwanji providing legal counsel.
Entrepreneur Staff

Entrepreneur Staff

Editor

For more than 30 years, Entrepreneur has set the course for success for millions of entrepreneurs and small business owners. We'll teach you the secrets of the winners and give you exactly what you need to lay the groundwork for success.

Most Popular

See all
Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2025.

By Eve Gumpel
Branding

Creating a Brand: How To Build a Brand From Scratch

Every business needs good branding to succeed. Discover the basics and key tips to building a successful brand in this detailed guide.

By John Williams
Innovation

It's Time to Rethink Research and Development. Here's What Must Change.

R&D can't live in a lab anymore. Today's leaders fuse science, strategy, sustainability and people to turn discovery into real-world value.

By Anantha Desikan
Marketing

How to Better Manage Your Sales Process

Get your priorities in order, and watch sales roll in.

By Tony Parinello
Business News

AI Agents Can Help Businesses Be '10 Times More Productive,' According to a Nvidia VP. Here's What They Are and How Much They Cost.

In a new interview with Entrepreneur, Nvidia's Vice President of AI Software, Kari Briski, explains how AI agents will "transform" the way we work — and sooner than you think.

By Sherin Shibu
Starting a Business

Passion-Driven vs. Purpose-Driven Businesses — What's the Difference, and Why Does It Matter?

Passion and purpose are both powerful forces in entrepreneurship, but they are not the same.

By Athalia Monae